Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view

@article{Diaz2003AssessmentOT,
  title={Assessment of the results from the phase I/II boron neutron capture therapy trials at the Brookhaven National Laboratory from a clinician’s point of view},
  author={Aidnag Z. Diaz},
  journal={Journal of Neuro-Oncology},
  year={2003},
  volume={62},
  pages={101-109}
}
Boron neutron capture therapy (BNCT) represents a promising modality for a relatively selective radiation dose delivery to the tumor tissue. The key to effective BNCT of tumors such as glioblastoma multiforme (GBM) is the homogeneous preferential accumulation of10B in the tumor, including the infiltrating GBM cells, as compared to that in the vital structures of the normal brain. Provided that sufficiently high tumor10B concentration (∼109 boron-10 atoms/cell) and an adequate thermal neutron… CONTINUE READING